Haisco Pharmaceutical Group (688302.SH) announced its semi-annual financial results, with a net loss attributable to shareholders of 61.85 million yuan.

Zhtng cijng APP news, Haichuang Pharmaceutical (688302.SH) disclosed its 2025 interim report, reporting that the company achieved revenue of 13.17 million yuan during the reporting period, an increase of 11,899.08% year-on-year; the net profit attributable to the shareholders of the listed company was a loss of 61.85 million yuan; the non-recurring net profit was a loss of 73.01 million yuan; basic earnings per share was -0.62 yuan.